Table 1.
Baseline characteristics across interleukin-6 and interleukin-18 tertiles at Atherosclerosis Risk in Communities Visit 5
| IL-6 (pg/mL) | IL-18 (pg/mL) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Risk factors | Overall (N = 5672) | 1st tertile (0.014–2.349, n = 1892) | 2nd tertile (2.351–3.947, n = 1891) | 3rd tertile (3.949–75.000, n = 1889) | P trend | 1st tertile (12.5–154.4, n = 1894) | 2nd tertile (154.5–232.0, n = 1890) | 3rd tertile (232.1–2347.1, n = 1888) | P trend |
| Age, years | 75.4 ± 5.1 | 74.6 ± 4.8 | 75.5 ± 5.1 | 76.2 ± 5.3 | <0.001 | 75.3 ± 5.1 | 75.4 ± 5.1 | 75.6 ± 5.2 | 0.108 |
| Black, % | 22.2 | 19.4 | 21.9 | 25.4 | <0.001 | 31.5 | 19.6 | 15.5 | <0.001 |
| Female, % | 58.0 | 61.0 | 57.9 | 55.1 | <0.001 | 67.5 | 57.1 | 49.4 | <0.001 |
| Prevalent CHD, % | 15.7 | 11.1 | 15.8 | 20.2 | <0.001 | 13.4 | 17.3 | 16.3 | 0.015 |
| Prevalent ischaemic stroke, % | 3.7 | 2.8 | 2.5 | 5.7 | <0.001 | 3.2 | 3.9 | 4.0 | 0.192 |
| Prevalent HF hospitalization, % | 13.6 | 6.9 | 11.8 | 22.0 | <0.001 | 12.0 | 13.4 | 15.3 | 0.004 |
| Prevalent global CVD, % | 28.3 | 19.5 | 27.4 | 38.1 | <0.001 | 25.9 | 29.2 | 29.9 | 0.007 |
| BMI, kg/m2 | 28.7 ± 5.7 | 26.7 ± 4.3 | 29.1 ± 5.3 | 30.4 ± 6.5 | <0.001 | 28.3 ± 5.7 | 28.7 ± 5.7 | 29.2 ± 5.7 | <0.001 |
| SBP, mmHg | 130.3 ± 18.2 | 129.4 ± 17.3 | 130.7 ± 18.4 | 130.7 ± 18.9 | 0.049 | 130.3 ± 18.1 | 130.3 ± 18.6 | 130.2 ± 18.0 | 0.544 |
| DBP, mmHg | 66.3 ± 10.8 | 66.5 ± 10.6 | 66.4 ± 10.3 | 65.9 ± 11.4 | 0.107 | 66.5 ± 10.6 | 66.2 ± 10.8 | 66.1 ± 10.8 | 0.149 |
| Pulse pressure, mmHg | 64.0 ± 14.7 | 62.9 ± 14.2 | 64.3 ± 15.1 | 64.8 ± 14.8 | <0.001 | 63.7 ± 14.7 | 64.1 ± 15.0 | 64.2 ± 14.4 | 0.433 |
| Heart rate, b.p.m. | 65.1 ± 10.9 | 64.0 ± 10.2 | 64.8 ± 10.9 | 66.5 ± 11.5 | <0.001 | 64.5 ± 10.7 | 65.1 ± 11.0 | 65.7 ± 10.9 | 0.002 |
| Hypertension, % | 74.3 | 66.3 | 75.5 | 81.3 | <0.001 | 73.5 | 74.5 | 75.0 | 0.284 |
| Antihypertensive medication use, % | 75.1 | 65.4 | 77.0 | 82.9 | <0.001 | 73.2 | 74.5 | 77.7 | 0.001 |
| Diabetes, % | 32.3 | 24.6 | 34.3 | 37.9 | <0.001 | 29.2 | 31.4 | 36.2 | <0.001 |
| Current smoking, % | 5.9 | 4.8 | 5.9 | 7.0 | 0.003 | 5.6 | 6.7 | 5.4 | 0.801 |
| Total cholesterol, mg/dL | 181.5 ± 42.0 | 188.2 ± 40.5 | 181.0 ± 41.8 | 175.2 ± 42.5 | <0.001 | 185.2 ± 41.7 | 181.0 ± 41.5 | 178.3 ± 42.4 | <0.001 |
| HDL-C, mg/dL | 52.2 ± 13.9 | 56.1 ± 14.5 | 51.3 ± 13.4 | 49.1 ± 12.9 | <0.001 | 56.2 ± 14.9 | 51.7 ± 12.7 | 48.6 ± 13.1 | <0.001 |
| Fasting glucose, mg/dL | 113.3 ± 27.8 | 109.3 ± 22.8 | 115.2 ± 29.8 | 115.4 ± 29.8 | <0.001 | 110.5 ± 25.7 | 112.9 ± 25.9 | 116.6 ± 31.2 | <0.001 |
| hs-CRP, mg/L | 2.0 (1.0, 4.2) | 1.1 (0.6, 2.0) | 2.0 (1.1, 3.7) | 3.9 (1.9, 7.8) | <0.001 | 1.7 (0.8, 3.5) | 2.0 (0.9, 4.1) | 2.4 (1.2, 4.9) | <0.001 |
| Lipid-lowering medication use, % | 56.5 | 53.8 | 58.1 | 57.5 | 0.021 | 57.4 | 56.5 | 55.6 | 0.268 |
| eGFR, mL/min/1.73m2 | 69.7 ± 17.2 | 73.3 ± 14.9 | 69.6 ± 16.9 | 66.1 ± 19.0 | <0.001 | 72.1 ± 16.4 | 69.9 ± 17.0 | 67.0 ± 17.9 | <0.001 |
Data presented as mean ± SD, median (25th percentile, 75th percentile), or per cent; P trend was calculated by sum of ranks trend test across ordered groups.
Abbreviations: BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HF, heart failure; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; IL-18, interleukin-18; SBP, systolic blood pressure.